Acute liver injury due to flavocoxid (Limbrel), A medical food for osteoarthritis: A case series

Annals of Internal Medicine

Volumn 156, Issue 12, 2012, Pages 857-860

  Chalasani, Naga ^a   Vuppalanchi, Raj ^a   Navarro, Victor ^b   Fontana, Robert ^c   Bonkovsky, Herbert ^d   Barnhart, Huiman ^e   Kleiner, David E ^f   Hoofnagle, Jay H ^g  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d LEVINE CANCER INSTITUTE   (United States)

^e DUKE UNIVERSITY   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DULOXETINE; FLAVOCOXID; FLAVONOID; HEPATITIS E ANTIBODY; IMMUNOGLOBULIN M; LIMBREL; PREGABALIN; TIZANIDINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE HEPATITIS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CHRONIC HEPATITIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG FEVER; DRUG WITHDRAWAL; EPIDEMIOLOGY; FEMALE; FEVER; HEPATITIS E VIRUS; HUMAN; JAUNDICE; LIVER BIOPSY; LIVER INJURY; MAJOR CLINICAL STUDY; MUSCULOSKELETAL PAIN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; SIDE EFFECT;

EID: 84862734518     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-156-12-201206190-00006     Document Type: Article

References (16)

1. Primus Pharmaceuticals: Limbrel Web site. Accessed at www.limbrel.com on 3 March 2012.
2. Primus Pharmaceuticals. Limbrel Product Information. Scottsdale, AZ: Primus Pharmaceuticals; 2011. Accessed at www.limbrel.com/downloads/limbrel_pi.pdf on 3 March 2012.
3. U.S. Food and Drug Administration. Medical Foods. Silver Spring, MD: U.S. Department of Health and Human Services; 2009. Accessed at www.fda.gov /food/foodsafety/product-specificinformation/medicalfoods on 3 March 2012.
4. Morgan SL, Baggott JE, Moreland L, Desmond R, Kendrach AC. The safety of flavocoxid, a medical food, in the dietary management of knee osteoarthritis. J Med Food. 2009;12:1143-8. [PMID: 19857081]
5. Levy RM, Khokhlov A, Kopenkin S, Bart B, Ermolova T, Kantemirova R, et al. Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: a randomized multicenter controlled trial in subjects with osteoarthritis of the knee. Adv Ther. 2010;27:731-42. [PMID: 20845002]
6. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al; DILIN Study Group. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32:55-68. [PMID: 19132805]
7. Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, et al; US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51:2117-26. [PMID:20512999]
8. Davern TJ, Chalasani N, Fontana RJ, Hayashi PH, Protiva P, Kleiner DE, et al; Drug-Induced Liver Injury Network (DILIN). Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011;141:1665-72. e1-9. [PMID: 21855518]
9. Pillai L, Burnett BP, Levy RM; GOAL Study Cooperative Group. GOAL: multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin. Curr Med Res Opin. 2010;26:1055-63. [PMID: 20225990]
10. Levy RM. Flavocoxid and hypersensitivity pneumonitis [Letter]. Chest. 2011;140:827-8; author reply 828. [PMID: 21896531]
11. Qiao H, Han H, Hong D, Ren Z, Chen Y, Zhou C. Protective effects of baicalin on carbon tetrachloride induced liver injury by activating PPAR_ and inhibiting TGF_1. Pharm Biol. 2011;49:38-45. [PMID: 20687787]
12. Guo HX, Liu DH, Ma Y, Liu JF, Wang Y, Du ZY, et al. Long-term baicalin administration ameliorates metabolic disorders and hepatic steatosis in rats given a high-fat diet. Acta Pharmacol Sin. 2009;30:1505-12. [PMID: 19890358]
13. Bonkovsky HL. Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis) [Letter]. Ann Intern Med. 2006;144:68-71. [PMID: 16389263]
14. Mazzanti G, Menniti-Ippolito F, Moro PA, Cassetti F, Raschetti R, Santuccio C, et al. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol. 2009;65:331-41. [PMID:19198822]
15. Schmidt M, Schmitz HJ, Baumgart A, Guédon D, Netsch MI, Kreuter MH, et al. Toxicity of green tea extracts and their constituents in rat hepatocytes in primary culture. Food Chem Toxicol. 2005;43:307-14. [PMID: 15621343]
16. U.S. Food and Drug Administration. Guidance for Industry: Frequently Asked Questions About Medical Foods. Silver Spring, MD: U.S. Department of Health and Human Services; 2007. Accessed at www.fda.gov/Food/Guidance ComplianceRegulatoryInformation/GuidanceDocuments/MedicalFoods/ucm054048.htm on 2 January 2012.